Stableford Capital II LLC Sells 16,958 Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Stableford Capital II LLC lessened its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 40.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,144 shares of the company's stock after selling 16,958 shares during the quarter. Stableford Capital II LLC owned 0.09% of Establishment Labs worth $1,001,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Capital Research Global Investors bought a new position in shares of Establishment Labs during the first quarter valued at about $45,888,000. William Blair Investment Management LLC grew its stake in shares of Establishment Labs by 14.5% during the second quarter. William Blair Investment Management LLC now owns 481,572 shares of the company's stock valued at $21,883,000 after buying an additional 60,848 shares during the last quarter. Bamco Inc. NY grew its stake in shares of Establishment Labs by 28.4% during the first quarter. Bamco Inc. NY now owns 429,775 shares of the company's stock valued at $21,876,000 after buying an additional 95,000 shares during the last quarter. Sofinnova Investments Inc. grew its stake in shares of Establishment Labs by 204.1% during the second quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company's stock valued at $19,505,000 after buying an additional 288,082 shares during the last quarter. Finally, First Turn Management LLC bought a new position in shares of Establishment Labs during the second quarter valued at about $16,812,000. Institutional investors own 72.91% of the company's stock.

Establishment Labs Stock Up 0.9 %

ESTA traded up $0.38 on Wednesday, hitting $42.91. The company had a trading volume of 234,966 shares, compared to its average volume of 377,219. The company has a debt-to-equity ratio of 4.30, a current ratio of 4.44 and a quick ratio of 2.91. Establishment Labs Holdings Inc. has a 52-week low of $16.96 and a 52-week high of $60.12. The stock has a fifty day simple moving average of $42.71 and a 200-day simple moving average of $46.69. The firm has a market capitalization of $1.18 billion, a P/E ratio of -13.54 and a beta of 1.20.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. The company had revenue of $44.12 million during the quarter, compared to analysts' expectations of $43.10 million. During the same quarter last year, the business earned ($0.65) earnings per share. The business's quarterly revenue was down 9.2% on a year-over-year basis. As a group, equities analysts expect that Establishment Labs Holdings Inc. will post -2.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ESTA shares. Citigroup raised their price objective on Establishment Labs from $45.00 to $50.00 and gave the company a "neutral" rating in a research note on Tuesday, October 1st. Stephens reiterated an "overweight" rating and set a $68.00 target price on shares of Establishment Labs in a report on Wednesday, August 7th. JPMorgan Chase & Co. dropped their target price on shares of Establishment Labs from $61.00 to $50.00 and set an "overweight" rating for the company in a report on Wednesday, August 7th. Finally, BTIG Research increased their target price on shares of Establishment Labs from $62.00 to $65.00 and gave the stock a "buy" rating in a report on Monday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $58.83.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.